Lithium Carbonate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | LITHONATE | — | 1970-04-06 | fda.gov ↗ |
Trials 48 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 12 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01354483 Background | Sep 2011 → Sep 2013 | spinal cord injury | China Spinal Cord Injury Network | Completed | No outcome recorded |
| Phase 1/2 | NCT00240110 Background | Mar 2006 → Mar 2014 | bipolar disorder, cocaine dependence | University of Miami | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01189812 Comparator | Mar 2010 → Jan 2011 | borderline personality disorder, dysthymic disorder, major depressive disorder | Columbia Northwest Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00818389 Comparator | Jan → Oct 2009 | amyotrophic lateral sclerosis | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00789854 Comparator | Nov 2008 → Aug 2009 | major depressive disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00000369 Background | Jun 1997 → Dec 2002 | bipolar I disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT04691700 Comparator | Jan 2021 → Dec 2027 expected | heart failure | Takeshi Morimoto | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04222816 Background | Jan 2020 → Dec 2021 | bipolar disorder | All India Institute of Medical Sciences, Bhubaneswar | Completed | No outcome recorded |
| Phase 4 | NCT03148535 Background | Jun 2017 → Dec 2018 | bipolar depression | Peking University | Unknown | No outcome recorded |
| Phase 4 | NCT03210480 Comparator | Mar 2017 → Sep 2019 | bipolar disorder | Angelini Pharma | Terminated | No outcome recorded |
| Phase 4 | NCT00641927 Comparator | Apr 2002 → Oct 2006 | bipolar II disorder | Stanley Medical Research Institute | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01146288 Background | Jul 2010 → May 2014 | medulloadrenal hyperfunction | Rabin Medical Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 62 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lithium carbonate | “we propose a clinical trial to study the security and efficacy of lithium carbonate targeting the patients with TBR1-related disorders” NCT06776848 ↗59“Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.” NCT03204500 ↗ “will be treated with lithium carbonate orally achieving a serum level of 0.2-0.4 mmol/l between month 6 and 12.” PMID 35962368 ↗ Aug 2022 “Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests” NCT01146288 ↗ “lithium carbonate” NCT00986128 ↗ |
| Known as | lithium | “The primary goal of this investigation is to examine the additive prophylactic potential of an individual psychotherapy based on interpersonal and social rhythm principles in...” NCT00000369 ↗2“To test whether low-dose lithium carbonate ameliorates disability accumulation in progressive MS, patients with progressive MS were randomly assigned to take lithium in either...” NCT01259388 ↗ “lithium carbonate (lithium)” NCT01754883 ↗ |
| Known as | Standard Treatment | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04691700 ↗ |
| Action | Inhibit | “Recent evidence points to the inhibition of the enzyme glycogen synthase kinase-3beta (GSK3) as one of its mechanisms of action.” NCT01055392 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Goreisan, a traditional Japanese herbal medicine” PMID 36841318 ↗ Feb 2023 |
| Route | Oral | “oral lithium treatments” NCT00431171 ↗ |